Applying the Minimally Important Difference of Health Utility Scores in the Calculation of Quality-Adjusted Life Years From Patient-Level Data

Poster (PDF) Presenter: Nathan McClure, School of Public Health, University of Alberta Background: In cost-utility analyses, the quality-adjusted life year (QALY) is calculated as the area under the curve (AUC) for the combined assessments of time and health-related quality of life (i.e., health utility score, or HUS). However, patients in a study may start at … Continued

What Factors Drive Positive CADTH pan-Canadian Oncology Drug Review Recommendations for Notice of Compliance With Conditions Submissions?

Poster (PDF) Presenter: Orest Kobelak, University of Toronto, Roche Background: Notice of Compliance with Conditions (NOC/c) status allows for earlier access to potentially life-saving therapies that demonstrate promising clinical effectiveness. Objective: This study examined whether pCODR recommendations for NOC/c submissions were driven by the presence of mature progression-free survival (PFS) and/or overall survival (OS) data, … Continued

Assistive Health Technology for Individuals With Dual Sensory Impairment: A Systematic Review

Poster (PDF) Presenter: Dr. Atul Jaiswal, University of Montrealemail: atul.jaiswal@umontreal.ca Co-Authors: Erin Perfect, Queen’s UniversityDr. Claire Davies, Queen’s University Background: Assistive health technology, a subset of health technology that encompasses assistive devices and services, is one of the most powerful tools for people with impairments. The need for assistive technologies is increasing with the age-related … Continued

Cost-Utility Analysis of the Electronic Patient Reported Outcomes (ePRO) Tool: An e-Health Solution for Community-Dwelling Complex Seniors in Ontario

Poster (PDF) Presenter: Aunima Bhuiya, Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto email: aunima.bhuiya@mail.utoronto.ca Co-Authors:Rafael Miranda,  Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto Zakariya Thraya, Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public … Continued

Impact of Patented Medicine Prices Review Board New Reference Countries on Drug Prices in Canada: A Comparison of Current and Anticipated List Prices for Top Drugs in the Country

Poster (PDF) Presenter: Chloé Langevin, Université de Montréalemail : chloe.langevin@umontreal.ca Objective: To assess the impact on list prices in Canada of modifying the basket of reference countries used by the Patented Medicine Prices Review Board (PMPRB). Methods: Fifteen therapeutic classes were selected from the 2019 Canadian Institute for Health Information report on prescribed drug spending in … Continued

Biosimilar Transitioning — A Private Payer’s Journey

Poster (PDF) Presenter: Dr. Anar Dossa, Pacific Blue Crossemail: adossa@pac.bluecross.ca Introduction: Canada has the second-highest per capita expenditure on biologics of all OECD‒Organisation for Economic Co-operation and Development countries and has approved far fewer biosimilar medications than the European Medicines Agency. Private insurance companies in Canada have been slow to adopt and implement robust strategies … Continued

The New Paradigm: Basket Studies in Oncology

Poster (PDF) Presenter: Marie-Eve Tremblay, Institut national d’excellence en santé et en services sociaux (INESSS)email: marie-eve.tremblay@inesss.qc.ca Background: Basket studies are defined by using a drug targeting a biomarker rather than a type of tumour, as conventional clinical trials in oncology. There is no guideline on how to design and evaluate such trials. A better understanding … Continued

Effectiveness and Patient Satisfaction with Treatment Options for Hidradenitis Suppurativa in Canada: Results from the Hidradenitis Suppurativa Patient Experience Survey

Poster (PDF) Presenter: Rachael Manion, Canadian Skin Patient AllianceTwitter Handle: @CanadianSkin Hidradenitis suppurativa (HS) is a painful dermatological condition affecting up to 4% of Canadians and characterized by recurrent and malodorous nodules in skin folds. We conducted a comprehensive international survey to understand patient experiences with HS treatments. In January 2020, we conducted an online … Continued